#News for #Investors and #Media: Today our specialist HIV company, ViiV Healthcare, announced phase III study results in #HIV evaluating a long-acting option versus daily oral therapy.
Our mission: to leave no person living with HIV behind.
👉 Find out more: gsk.to/1645
